GlassScriptPhysician profile
Jane D Skelton
NPI 1225086051
$4,196.76
in general payments reported to CMS, 2019-2025
32 companies · $1,145 in 2025
The $1,145 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,270 · 2020: $290 · 2021: $11.92 · 2022: $142 · 2023: $183 · 2024: $1,155 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,181 · Food and Beverage: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,181.47 |
| Food and Beverage | $301.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,226.99 | 2019-2025 | |
| Janssen Biotech, INC. | $356.94 | 2019-2025 | Erleada, Balversa, Akeega |
| Seagen INC. | $211.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $179.80 | 2019-2025 | Enhertu |
| Puma Biotechnology, INC. | $174.22 | 2019-2025 | |
| Daiichi Sankyo INC. | $144.86 | 2020-2023 | Enhertu |
| Lilly USA, LLC | $123.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $80.24 | 2019 | |
| Genentech USA, INC. | $77.06 | 2019 | |
| Merck Sharp & Dohme LLC | $76.33 | 2019 | |
| Genzyme Corporation | $62.16 | 2019-2020 | |
| Gilead Sciences, INC. | $54.31 | 2021-2025 | Trodelvy |
| Celgene Corporation | $36.91 | 2019 | |
| Incyte Corporation | $35.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.45 | 2019-2025 | Ninlaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $33.77 | 2019 | |
| Dova Pharmaceuticals | $28.36 | 2019-2020 | |
| Tempus Ai, INC | $27.24 | 2024 | Xt Cdx |
| Amgen INC. | $23.84 | 2019 | |
| Beone Medicines USA, INC. | $23.39 | 2025 | Brukinsa |
| Foundation Medicine, INC. | $22.97 | 2019 | |
| Immunogen, INC. | $22.04 | 2023 | Elahere |
| Kyowa Kirin, INC. | $21.58 | 2019 | |
| Eisai INC. | $20.71 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.12 | 2020 | |
| Sun Pharmaceutical Industries INC. | $17.81 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.14 | 2019 | |
| Pfizer INC. | $15.67 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.33 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.02 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Skelton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.